Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)

Wolfgang WillenbacherDepartment of Internal Medicine, University Hospital for Internal Medicine V (Haematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria; ;Area 4 Health Technology Assessment and Bioinformatics, ONCOTYROL – Center for Personalized Cancer Medicine, Innsbruck, Austria;

Shanmugapriya ThangavadivelTyrolean Cancer Research Institute, Innsbruck, Austria;

Richard GreilTyrolean Cancer Research Institute, Innsbruck, Austria; ;Laboratory of Immunological and Molecular Cancer Research, Salzburg Cancer Research Institute, Salzburg, Austria;

Ella WillenbacherDepartment of Internal Medicine, University Hospital for Internal Medicine V (Haematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria;

Roman WegerArea 4 Health Technology Assessment and Bioinformatics, ONCOTYROL – Center for Personalized Cancer Medicine, Innsbruck, Austria;

Claudia ManzlDepartment of Pathology, Division of General Pathology, Medical University of Innsbruck, Innsbruck, Austria

Karin JöhrerTyrolean Cancer Research Institute, Innsbruck, Austria; Correspondence[email protected]

Andrea BrunnerDepartment of Pathology, Division of General Pathology, Medical University of Innsbruck, Innsbruck, AustriaCorrespondence[email protected]

show all

Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date